Pharma giant refused costs in HSE tender case

Because of its interest in the outcome, the pharmaceutical giant was joined as a notice party to a Commercial Court action brought by Sanofi against the HSE’s awarding of a tender for the six-in-one vaccine last January

30th December, 2018

Glaxosmithkline has been refused most of its costs following a legal row in which it said the “safety and efficacy” of one of its vaccines was being challenged by a global rival.

Because of its interest in the outcome, the pharmaceutical giant was joined as a notice party to a Commercial Court action brought by Sanofi against the HSE’s awarding of a tender for the six-in-one vaccine last January.

Glaxo beat...

Subscribe from just €1 for the first month!

Exclusive offers:

All Digital Access + eReader

Trial

€1

Unlimited Access for 1 Month, €19.99 Monthly thereafter

Get basic

*New subscribers only

You can cancel any time.

Annual

€200

€149 For the 1st Year

Unlimited Access for 1 Year

You can cancel any time.

Quarterly

€55

€42

90 Day Pass

You can cancel any time.

2 Yearly

€315

€248

Unlimited Access for 2 Years

You can cancel any time.

Team Pass

Get a Business Account for you and your team

Share this post

Related Stories

Some people with cystic fibrosis still awaiting Covid-19 vaccine, charity warns

Health Donal MacNamee 2 days ago

Top medic: ‘If the state can pay for Viagra, it can pay for extreme pregnancy sickness drugs’

Health Daniel Murray 1 week ago

Over 300 administered vaccine doses not recorded as given to priority groups

Health Rachel Lavin 1 week ago

Praxis Care to hire 400 new carers as demand for services grows